You are here: Industry Insights > Trodelvy

News List

Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer prnasia
January 11, 2022
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), today announced it will participate in a study pursuant to a clinical trial collaboration between Gilead and MSD...
Gilead’s Trodelvy scores accelerated approval in advanced bladder cancer pharmatimes
April 15, 2021
Gilead’s antibody drug conjugate (ADC) Trodelvy has received an accelerated approval from the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic urothelial cancer (UC), the most common form of bladder cancer.
Gilead gets US FDA Accelerated Approval for Trodelvy to treat metastatic urothelial cancer expresspharma
April 15, 2021
Gilead Sciences announced that the US Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously ...
Gilead gets US FDA nod for Trodelvy to treat metastatic triple-negative breast cancer expresspharma
April 09, 2021
Trodelvy significantly reduced the risk of death by 49 per cent compared with single-agent chemotherapy in the Phase 3 ASCENT Study.
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression prnasia
April 02, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the ...
First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy for Breast Cancer americanpharmaceuticalreview
December 30, 2020
Everest Medicines announced the first patient has been dosed in the Phase 3 registration Asian study EVER-132-002 evaluating TrodelvyTM (sacituzumab govitecan) versus treatment of physician’s choice (TPC) in subjects with hormonal ...
First Patient Dosed in Trodelvy Trial for Metastatic Triple-Negative Breast Cancer americanpharmaceuticalreview
November 12, 2020
Everest Medicines announced the first patient has been dosed in China into the EVER-132-001 Phase 2b registration clinical trial evaluating Trodelvy (sacituzumab govitecan, IMMU-132) for the treatment of patients with metastatic triple-negative ...
Trodelvy from Immunomedics gets US FDA orphan drug designation for glioblastoma expresspharma
October 14, 2020
Trodelvy has shown encouraging activity in an early-stage study in brain cancers, including partial responses in small cohorts of patients with brain metastasis from breast cancer and recurrent glioblastoma, informed the company.
Trodelvy from Immunomedics extends survival in breast cancer patients expresspharma
September 21, 2020
The FDA granted the drug accelerated approval for its use in metastatic triple-negative breast cancer (mTNBC) patients who had previously received at least two prior therapies.
Gilead agrees to acquire Immunomedics for $21bn pharmaceutical-technology
September 15, 2020
Gilead Sciences has signed a definitive agreement to acquire cancer therapies developer Immunomedics for a total consideration of approximately $21bn, or $88 per share.

Previous page 1 2 Next page